Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single‐institution study

We have been able to use molecular targeted agents for unresectable hepatocellular carcinoma since 2009, and immune checkpoint inhibitors have been approved in recent years. We assessed the efficacy of systemic therapy in Hiroshima University Hospital by each era.